Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,488 | 62 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $472.98 | 26 | $0 (2024) |
| Galderma Laboratories, L.P. | $219.84 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $143.19 | 8 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | $0 (2023) |
| GENZYME CORPORATION | $97.52 | 5 | $0 (2024) |
| UCB, Inc. | $76.86 | 3 | $0 (2023) |
| Lilly USA, LLC | $75.75 | 4 | $0 (2023) |
| Janssen Biotech, Inc. | $55.08 | 3 | $0 (2023) |
| Amgen Inc. | $52.69 | 2 | $0 (2023) |
| LEO Pharma Inc. | $43.06 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $170.96 | 12 | ABBVIE INC. ($130.89) |
| 2023 | $627.06 | 25 | ABBVIE INC. ($322.82) |
| 2022 | $239.52 | 12 | Novartis Pharmaceuticals Corporation ($72.01) |
| 2021 | $450.46 | 13 | Galderma Laboratories, L.P. ($219.84) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 3 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: DERMATOLOGY | ||||||
| 11/17/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: IMMUNOLOGY | ||||||
| 10/21/2021 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: IMMUNOLOGY | ||||||
| 10/13/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.10 | General |
| Category: Dermatology | ||||||
| 10/06/2021 | Ortho Dermatologics, a division of Bausch Health US, LLC | ARAZLO (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Dermatology | ||||||
| 10/05/2021 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: Immunology | ||||||
| 09/29/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: IMMUNOLOGY | ||||||
| 09/15/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/10/2021 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $219.84 | General |
| 08/25/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $28.84 | General |
| Category: Immunology | ||||||
| 08/18/2021 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 2,660 | 3,856 | $488,965 | $175,813 |
| 2022 | 11 | 1,103 | 1,559 | $192,973 | $62,938 |
| 2021 | 10 | 771 | 1,211 | $132,080 | $27,363 |
| 2020 | 6 | 288 | 415 | $38,372 | $10,004 |
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 441 | 441 | $86,436 | $29,204 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 340 | 407 | $64,306 | $25,448 | 39.6% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 327 | 350 | $59,278 | $24,348 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 229 | 229 | $68,013 | $24,151 | 35.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 480 | 551 | $63,492 | $20,927 | 33.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 223 | 248 | $49,837 | $20,046 | 40.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 161 | 200 | $44,600 | $17,337 | 38.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 342 | 1,276 | $33,176 | $6,063 | 18.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 71 | 106 | $10,282 | $4,156 | 40.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 17 | 19 | $4,332 | $1,849 | 42.7% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 15 | $3,828 | $1,689 | 44.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 14 | $1,386 | $593.32 | 42.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 152 | 152 | $29,716 | $10,554 | 35.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 116 | 117 | $21,012 | $7,396 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 62 | 62 | $18,428 | $7,375 | 40.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 111 | 116 | $16,848 | $6,855 | 40.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 173 | 176 | $22,921 | $6,846 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 65 | $13,993 | $6,247 | 44.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 71 | 76 | $15,478 | $5,460 | 35.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 40 | 40 | $7,880 | $2,083 | 26.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 137 | 493 | $14,347 | $2,071 | 14.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 27 | 47 | $4,629 | $1,709 | 36.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 36 | 37 | $4,884 | $1,675 | 34.3% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 12 | 14 | $2,836 | $1,164 | 41.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 33 | 33 | $5,379 | $1,100 | 20.5% |
About Dr. Jacob Inda, MD
Dr. Jacob Inda, MD is a Dermatology healthcare provider based in Missoula, Montana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/10/2016. The National Provider Identifier (NPI) number assigned to this provider is 1275997827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacob Inda, MD has received a total of $1,488 in payments from pharmaceutical and medical device companies, with $170.96 received in 2024. These payments were reported across 62 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($1,488).
As a Medicare-enrolled provider, Inda has provided services to 4,822 Medicare beneficiaries, totaling 7,041 services with total Medicare billing of $276,118. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Missoula, MT
- Active Since 04/10/2016
- Last Updated 10/04/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1275997827
Products in Payments
- SKYRIZI (Biological) $254.54
- RINVOQ (Biological) $218.44
- COSENTYX (Biological) $143.19
- DUPIXENT (Biological) $127.00
- SPEVIGO (Drug) $125.00
- Cimzia (Drug) $76.86
- TALTZ (Drug) $75.75
- Otezla (Drug) $52.69
- OPZELURA (Drug) $36.95
- REMICADE (Biological) $33.33
- ADBRY (Biological) $27.94
- ARAZLO (Drug) $24.98
- TREMFYA (Drug) $21.75
- Puraply (Medical Supply) $17.44
- ENSTILAR (Drug) $15.12
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Missoula
Shannon Foster, M.d, M.D
Dermatology — Payments: $11,217
Troy Davis, Pa-C, PA-C
Dermatology — Payments: $5,646
Jessica Sempler, M.d, M.D
Dermatology — Payments: $5,358
Andrew Tegeder, Md, MD
Dermatology — Payments: $3,539
Erika Hagstrom, Md, MD
Dermatology — Payments: $1,643
Allyson Yelich, D.o, D.O
Dermatology — Payments: $843.25